Pharmacokinetic and pharmacodynamic properties of insulin degludec in Japanese patients with type 1 diabetes mellitus reflect similarities with Caucasian patients
ConclusionsIDeg has a flat, consistent and ultra‐long glucose‐lowering effect that is evenly distributed across a 24‐h interval and an ultra‐long duration of action in Japanese patients with type 1 diabetes. These data support once‐daily dosing of IDeg in all patients. Overall, the pharmacodynamic and pharmacokinetic end‐points and safety observations are consistent with those previously reported in Caucasian patients.
This study aimed to evaluate the pharmacokinetic and pharmacodynamic properties of insulin degludec (IDeg) in Japanese patients with type 1 diabetes mellitus (T1DM). Patients were randomized into two treatment sequences and received IDeg or insulin detemir (IDet) for 6 days and a washout period (7–21 days) before switching treatment. IDeg has a flat, consistent and ultra‐long glucose‐lowering effect that is evenly distributed across a 24‐h interval and an ultra‐long duration of action in Japanese patients with type 1 diabetes mellitus; overall, the pharmacodynamic and pharmacokinetic endpoints and safety observations are consistent with those previously reported in Caucasian patients.
Source: Journal of Diabetes Investigation - Category: Endocrinology Authors: Ippei Ikushima, Kohei Kaku, Koichi Hirao, Lars Bardtrum, Hanne Haahr Tags: Clinical Trial Source Type: research
More News: Clinical Trials | Diabetes | Diabetes Mellitus | Diabetes Type 1 | Endocrinology | Eyes | Insulin | Levemir | Study | Women